Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

The AETHERA trial reported an increased progression‐free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high‐risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hematological oncology 2021-10, Vol.39 (4), p.498-505
Hauptverfasser: Akay, Olga Meltem, Ozbalak, Murat, Pehlivan, Mustafa, Yildiz, Birol, Uzay, Ant, Yigenoglu, Tugce Nur, Elverdi, Tugrul, Kaynar, Leylagul, Ayyildiz, Orhan, Yonal Hindilerden, Ipek, Goksoy, Hasan Sami, Izmir Guner, Sebnem, Gunes, Ahmet Kursad, Sonmez, Mehmet, Kurt Yuksel, Meltem, Civriz Bozdag, Sinem, Ozkurt, Zubeyde Nur, Toptas, Tayfur, Dogu, Mehmet Hilmi, Salim, Ozan, Saydam, Guray, Yavasoglu, Irfan, Ayli, Meltem, Ozet, Gulsum, Albayrak, Murat, Birtas Atesoglu, Elif, Toprak, Selami K., Yildirim, Rahsan, Mehtap, Ozgur, Kalayoglu Besisik, Sevgi, Nalcaci, Meliha, Altuntas, Fevzi, Ferhanoglu, Burhan
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Autografts
autologous stem cell transplantation
brentuximab vedotin
Confidence intervals
Consolidation
Fatalities
Hodgkin lymphoma
Hodgkin's lymphoma
Immunotherapy
Lymphoma
Maintenance
Monoclonal antibodies
Neutropenia
Patients
Peripheral neuropathy
relapsed and refractory
Risk
Stem cell transplantation
Stem cells
Survival
Targeted cancer therapy
Therapy
Toxicity
Transplantation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The AETHERA trial reported an increased progression‐free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high‐risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASCT in real‐world patients. Seventy‐five patients with relapsed/refractory HL started on BV consolidation therapy after ASCT due to high risk of relapse, between January 2016 and July 2019, from 25 institutions, were included in the study. The median follow‐up time was 26 months. The most common high‐risk features were primary refractory or relapsed disease
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2897